

# Femke Heindryckx

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3347403/publications.pdf>

Version: 2024-02-01

39  
papers

2,195  
citations

331259

21  
h-index

360668

35  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4211  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting ER stress in the hepatic tumor microenvironment. FEBS Journal, 2022, 289, 7163-7176.	2.2	23
2	Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells, 2022, 11, 632.	1.8	30
3	Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. Cells, 2021, 10, 1163.	1.8	10
4	Exploring the Role of Endoplasmic Reticulum Stress in Hepatocellular Carcinoma through mining of the Human Protein Atlas. Biology, 2021, 10, 640.	1.3	15
5	In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma. Cells, 2021, 10, 1717.	1.8	25
6	Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment. Life Sciences, 2021, 277, 119612.	2.0	14
7	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 13051.	1.8	14
8	Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype. International Journal of Molecular Sciences, 2020, 21, 8177.	1.8	17
9	Fibrin fragment E potentiates TGF- $\beta$ 2-induced myofibroblast activation and recruitment. Cellular Signalling, 2020, 72, 109661.	1.7	10
10	A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties. Journal of Visualized Experiments, 2020, , .	0.2	14
11	Inhibiting IRE1 $\beta$ -endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma. ELife, 2020, 9, .	2.8	27
12	Blocking IRE1 $\alpha$ -endoribonuclease activity in hepatic stellate cells decreases tumor cell proliferation and metastasis in hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S636.	1.8	0
13	Platelets as Key Factors in Hepatocellular Carcinoma. Cancers, 2019, 11, 1022.	1.7	59
14	Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019, 11, 1024.	1.7	41
15	Role of proteoglycans in neuro-inflammation and central nervous system fibrosis. Matrix Biology, 2018, 68-69, 589-601.	1.5	42
16	Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment. Journal of Hepatology, 2018, 68, S671-S672.	1.8	0
17	Endoplasmic reticulum stress in hepatic stellate cells contributes to the progression of hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S93.	1.8	0
18	Endoplasmic reticulum stress enhances fibrosis through $\text{IRE}\alpha$ -mediated degradation of miR-150 and XBP1 splicing. EMBO Molecular Medicine, 2016, 8, 729-744.	3.3	122

#	ARTICLE	IF	CITATIONS
19	Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. <i>PLoS ONE</i> , 2016, 11, e0162286.	1.1	25
20	Time-Dependent Effect of Hypoxia on Tumor Progression and Liver Progenitor Cell Markers in Primary Liver Tumors. <i>PLoS ONE</i> , 2015, 10, e0119555.	1.1	12
21	P0280 : Effect of extracellular matrix on cancer stem cells. <i>Journal of Hepatology</i> , 2015, 62, S412.	1.8	0
22	Hepatitis mouse models: from acute to chronic autoimmune hepatitis. <i>International Journal of Experimental Pathology</i> , 2014, 95, 309-320.	0.6	22
23	The roles of transforming growth factor- $\beta^2$ , Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours. <i>International Journal of Oncology</i> , 2014, 44, 1015-1022.	1.4	43
24	Targeting the tumor stroma in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2014, 7, 165.	0.8	66
25	The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. <i>Journal of Hepatology</i> , 2013, 58, 319-328.	1.8	26
26	The need for transparency and good practices in the qPCR literature. <i>Nature Methods</i> , 2013, 10, 1063-1067.	9.0	251
27	Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor. <i>Molecular and Cellular Biochemistry</i> , 2013, 372, 199-210.	1.4	8
28	New therapeutic targets in veterinary oncology: Man and dog definitely are best friends. <i>Veterinary Journal</i> , 2013, 195, 6-7.	0.6	11
29	Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. <i>Hepatology</i> , 2013, 57, 1793-1805.	3.6	74
30	MicroRNA-24 Suppression of N-Deacetylase/N-Sulfotransferase-1 (NDST1) Reduces Endothelial Cell Responsiveness to Vascular Endothelial Growth Factor A (VEGFA). <i>Journal of Biological Chemistry</i> , 2013, 288, 25956-25963.	1.6	28
31	The paradox of the unfolded protein response in cancer. <i>Anticancer Research</i> , 2013, 33, 4683-94.	0.5	132
32	Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1020-1032.	0.8	15
33	Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice. <i>Journal of Hepatology</i> , 2012, 57, 61-68.	1.8	21
34	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012, 59, 442-449.	1.4	100
35	Angiogenesis in chronic liver disease and its complications. <i>Liver International</i> , 2011, 31, 146-162.	1.9	226
36	Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. <i>Hepatology</i> , 2011, 53, 1629-1640.	3.6	78

#	ARTICLE	IF	CITATIONS
37	Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. <i>Molecular Cancer</i> , 2010, 9, 219.	7.9	36
38	Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease. <i>Cell</i> , 2010, 141, 178-190.	13.5	243
39	Experimental mouse models for hepatocellular carcinoma research. <i>International Journal of Experimental Pathology</i> , 2009, 90, 367-386.	0.6	314